Having trouble accessing articles? Reset your cache.

In with the ALK Crowd

Pfizer's crizotinib for NSCLC spurs Tesaro's ALK inhibitor deal with Amgen

Pfizer Inc.'s crizotinib has provided POC that targeting ALK can significantly improve response in a small subset of non-small cell lung cancer patients compared to current treatments. While the pharma completes it NDA submission, other companies are lining up behind it with second-generation programs that they believe will be more selective and more potent.

One of them is a newco, Tesaro Inc., which in-licensed Amgen Inc.'s ALK program last month.

In January, Pfizer began submission of a rolling NDA to FDA for crizotinib (PF-02341066). It is an oral small molecule dual inhibitor of c-Met receptor tyrosine kinase and anaplastic lymphoma kinase (ALK) and their oncogenic variants.

According to Darrel Cohen, senior director of oncology clinical development, the pharma originally planned to develop the small molecule based on its c-Met inhibitory properties because "we

Read the full 1307 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers